Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vanessa F Langness

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal of Translational Medicine|May 29, 2026
Taming the "death receptor": translating the first-in-class p75<sup>NTR</sup> modulator LM11A-31 from basic biology, across broad preclinical models, to clinical proof-of-conceptVanessa F Langness, Danielle A Simmons, Sukhneet Kaur, et al.
Molecular Biology of the Cell|December 9, 2020
Cholesterol-lowering drugs reduce APP processing to Aβ by inducing APP dimerizationVanessa F Langness, Rik van der Kant, Utpal Das, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 18, 2025
Twenty years of therapeutic development in tauopathy mouse models: a scoping reviewVanessa F Langness, Danielle A Simmons, Tyne L M McHugh, et al.
The Journal of Biological Chemistry|June 3, 2018
Full-length amyloid precursor protein regulates lipoprotein metabolism and amyloid-β clearance in human astrocytesLauren K Fong, Max M Yang, Rodrigo Dos Santos Chaves, et al.
Cell Stem Cell|January 29, 2019
Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer's Disease NeuronsRik van der Kant, Vanessa F Langness, Cheryl M Herrera, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal of Translational Medicine|May 29, 2026
Taming the "death receptor": translating the first-in-class p75<sup>NTR</sup> modulator LM11A-31 from basic biology, across broad preclinical models, to clinical proof-of-conceptVanessa F Langness, Danielle A Simmons, Sukhneet Kaur, et al.
Molecular Biology of the Cell|December 9, 2020
Cholesterol-lowering drugs reduce APP processing to Aβ by inducing APP dimerizationVanessa F Langness, Rik van der Kant, Utpal Das, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 18, 2025
Twenty years of therapeutic development in tauopathy mouse models: a scoping reviewVanessa F Langness, Danielle A Simmons, Tyne L M McHugh, et al.
The Journal of Biological Chemistry|June 3, 2018
Full-length amyloid precursor protein regulates lipoprotein metabolism and amyloid-β clearance in human astrocytesLauren K Fong, Max M Yang, Rodrigo Dos Santos Chaves, et al.
Cell Stem Cell|January 29, 2019
Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer's Disease NeuronsRik van der Kant, Vanessa F Langness, Cheryl M Herrera, et al.
Pageof 1